Stem cell transplantation for multiple sclerosis: What is the evidence?

Blood Reviews

Volumn 17, Issue 4, 2003, Pages 233-240

  Fassas, Athanasios ^a   Kimiskidis, Vassilios K ^a,b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Multiple sclerosis; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BUSULFAN; CARMUSTINE; CD34 ANTIGEN; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; FLUDARABINE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MITOXANTRONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGE; AGED; ANTIINFLAMMATORY ACTIVITY; AUTOTRANSPLANTATION; BLEEDING; CLINICAL TRIAL; DISABILITY; DISEASE EXACERBATION; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0242386264     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00022-5     Document Type: Review

References (72)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
3. Poser CM. Notes on the pathogenesis of multiple sclerosis. Clin Neurosci 1994; 2: 258-265.
4. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
5. Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 1999; 170: 11-18.
6. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
7. Weinstock-Guttman B, Jakobs LD. What is new in the treatment of multiple sclerosis?. Drugs 2000; 59: 401-410.
8. Polman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. Br Med J 2000; 321: 490-494.
9. Bitsch A, Bruck W. Differentiation of multiple sclerosis subtypes: implications for treatment. CNS Drugs 2002; 16: 405-418.
10. Kappos L, Polman C, Pozzilli C, Thomson A, Beckmann K, Dahlke F, European Study Group in Interferon beta-1b in Secondary-Progressive MS. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57: 1969-1975.
11. Goodkin DE, North American Study Group on Interferon beta-1b in Secondary Prevention MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 2000; 54 (Suppl.): 2352.
12. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001; 56: 1496-1504.
13. Hartung HP, Gonsette R, the MIMS-Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999; 52: A290.
14. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
15. Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol 2001; 13: 597-600.
16. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16: 183-200.
17. Ikehara S, Good RA, Nakamura T et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985; 82: 2483-2487.
18. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases. Stem Cells 1994; 12: 125-135.
19. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997; 99: 9-22.
20. Van Bekkum DW. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation. Clin Immunol Immunopathol 1998; 89: 1-10.
21. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol 1998; 99: 116-132.
22. Tyndall A, Fassas A, Passweg J et al., for the Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation (EBMT), the European League Against Rheumatism (EULAR) and on behalf of the International Stem Cell project for Autoimmune Disease. Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. Bone Marrow Transplant 1999; 24: 729-734.
23. Karussis DM, Slavin S, Ben-Nun A et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 1992; 39: 201-210.
24. Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantaiton. J Immunol 1992; 148: 1693-1698.
25. Karussis DM, Vourka-Karoussis U, Lehmann D et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1993; 92: 765-772.
26. van Gelder M, Kinwell-Bohre EPM, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant 1993; 11: 233-241.
27. van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995; 16: 343-351.
28. Burt RK, Ruvollo P, Hess A, Burns W. Syngeneic bone marrow transplantation in Lewis rats with experimental autoimmune encephalitis. J Neurosci Res 1995; 41: 526-531.
29. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1029-1034.
30. Karussis D, Vourka-Karussis U, Mizrachi-Koll R, Abramsky O. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long-lasting, antigen-specific tolerance by syngeneic bone marrow transplantation. Mult Scler 1999; 5: 17-21.
31. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6.
32. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997; 19: 395-397.
33. Meloni G, Salvetti M, Cordone I, Mancini M, Mandelli F. Autologous peripheral blood stem cell transplantation in a patient with multiple sclerosis and concomitant Ph+ acute leukemia. Haematologica 1999; 84: 665-667.
34. Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol 2000; 247: 691-695.
35. Fassas A, Anagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631-638.
36. Burt RK, Traynor AE, Cohen B et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21: 537-541.
37. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
38. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30.
39. Kozak T, Havrdova E, Pit'ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525-531.
40. Openshaw H, Lund BT, Kashyap A et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563-575.
41. Saiz A, Carreras E, Berenguer J et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001; 56: 563-575.
42. Mancardi GL, Saccardi R, Filippi M et al. Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001; 57: 62-68.
43. Carreras E, Saiz A, Marin P et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of the toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003; 88: 306-314.
44. Conference Synopsis: Hematopoietic stem cell therapy in autoimmune diseases, October 2001. Biol Blood Marrow Transplant 2002; 8: 407-411.
45. Lindsey ES, Woodruff MFA. Infusion of marrow and spleen cells in irradiated NZB/BI mice: amelioraiton of autoimmune disease. Br J Haematol 1968; 14: 255-260.
46. Ikehara S, Kawamura M, Takao F et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87: 8341-8344.
47. van Bekkum DW. Autologous stem cell therapy for treatment of autoimmune diseases. Exp Hematol 1998; 26: 831-834.
48. Ikehara S. Treatment of autoimmune disease by hematopoietic stem cell transplantation. Exp Hematol 2001; 29: 661-669.
49. Marmont AM. Perspective: immunoablation with stem cell rescue: a possible cure for systemic lupus erythematosus. Lupus 1993; 2: 151-156.
50. Slavin S. Treatment of life-threatening autoimmune disease with myeloablative doses of immunodepressive agents: experimental background and rationale for ABMT. Bone Marrow Transplant 1993; 12: 201-210.
51. Euler HH, Marmont A, Bacigalupo A et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996; 88: 3621-3625.
52. van Bekkum DW. New opportunities for the treatment of severe autoimmune diseases: bone marrow transplantation. Clin Immunol Immunopathol 1998; 89: 1-10.
53. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-350.
54. Marmont AM. Lupus: tinkering with haematopoietic stem cells. Lupus 2001; 10: 769-774.
55. Verburg RJ, Kruize AA, van den Hoogen FH et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum 2001; 44: 754-760.
56. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290: 1779-1782.
57. Fassas A, Passweg JR, Anagnostopoulos A et al., for the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation). Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol 2002; 249: 1088-1097.
58. Openshaw H, Stuve O, Antel JP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147-2150.
59. Burt RK, Fassas A, Snowden JA et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001; 28: 1-12.
60. Weinshenker BG, Issa M, Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 1996; 46: 1613-1619.
61. Kimiskidis VK, Tsimourtou V, Papagiannopoulos S et al. Autologous stem cell transplantation in multiple sclerosis: the MRI study. J Neurol 2002; 249 (Suppl. 1): 1/61.
62. Martinelli V, Gironi M, Rodegher M, Martino G, Comi G. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment. Ital J Neurol Sci 1998; 19: 65-67.
63. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-1695.
64. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol 1994; 21: 350-352.
65. Moake JL, Kent CJ, Meta LD, Wright LC. Circulating IgG antibodies against factors IX and VIII in multiple sclerosis. Acta Haematol 1976; 55: 53-59.
66. Saccardi R, Mancardi G, Bacigalupo A et al. Autologous hematopoietic stem cell transplantation in secondary progressive MS: clinical, MRI and laboratory findings. Bone Marrow Transplant 2002; 29(Suppl. 2): S13.
67. Kozak T, Havrdova E, Pitha J et al. Immunoablative therapy with PBPC support with in vitro or in vivo T-cell depletion in patients with poor risk multiple sclerosis. Bone Marrow Transplant 2002; 29(Suppl. 2): S15.
68. Burt RK, Cohen BA, Lobeck LJ, Oyama Y, Traynor A, Burns WH. Immune suppressive therapy with autologous hematopoietic stem cell transplantation arrests active CNS inflammation but not axonal atrophy in patients with severe disability and progressive multiple sclerosis. Blood 2001; 98: 687a.
69. Nash RA, Bowen JD, McSweeny PA et al. Treatment of severe multiple sclerosis with high-dose immunosuppressive therapy and autologous stem cell transplantation. Blood 2001; 98: 687a.
70. Comi G, Kappos L, Clanet M et al., the BMT-MS Study Group. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000; 247: 376-382.
71. Ghalie RG, Edan G, Laurent M et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909-913.
72. Ghalie RG, Mauch E, Edan G et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441-445.